CD8A and melanoma: In melanoma patients, coactivating Ag-specific CD4+ T cells with MHC-I/II peptide-loaded DCs augments Ag-specific CD8+ T-cell responses, which contributes to improved clinical responses, as compared to dacarbazine-treated control patients (99).